Physician profile
Jackson Chen
NPI 1710480892
$5,384.73
in general payments reported to CMS, 2019-2025
25 companies · $1,863 in 2025
The $1,863 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $34.72 · 2022: $43.53 · 2023: $1,313 · 2024: $2,130 · 2025: $1,863.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,303 · Education: $3.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,302.98 |
| Education | $3.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,701.94 | 2023-2025 | Airsupra, Breztri, Bevespi Aerosphere |
| Abbvie INC. | $743.30 | 2023-2025 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $383.29 | 2023-2025 | Zepbound, Mounjaro, Kisunla |
| Pfizer INC. | $373.99 | 2023-2025 | |
| Glaxosmithkline, LLC. | $312.10 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Novo Nordisk INC | $306.84 | 2023-2025 | Rybelsus, Ozempic |
| Teleflex LLC | $231.11 | 2023 | Urolift |
| Exact Sciences Corporation | $228.85 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Phathom Pharmaceuticals, INC. | $183.49 | 2024-2025 | Voquezna |
| Viatris Specialty LLC | $178.24 | 2025 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $139.04 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.98 | 2024 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.56 | 2023 | Jardiance |
| Cequr Corporation | $74.86 | 2023 | Cequr Simplicity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $54.64 | 2023-2024 | Caplyta |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $52.19 | 2024-2025 | Gemtesa |
| Corium, LLC | $44.72 | 2023-2024 | Azstarys |
| Medtronic, INC. | $20.29 | 2023 | Interstim |
| Merck Sharp & Dohme LLC | $19.93 | 2024 | Gardasil 9, Gardasil, Capvaxive |
| Agios Pharmaceuticals, INC. | $19.36 | 2025 | Pyrukynd |
| Hikma Pharmaceuticals USA | $17.36 | 2021 | |
| Eyevance Pharmaceuticals LLC | $17.36 | 2021 | |
| Axsome Therapeutics, INC. | $15.75 | 2025 | Auvelity |
| Seqirus USA INC | $14.94 | 2025 | Fluad, Flucelvax |
| Antares Pharma, INC. | $14.60 | 2025 | Xyosted |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jackson Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.